Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18202-027US1/1110US	Application No. 10/589,920
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant ZHI et al.	
		Filing Date August 17, 2006	Group Art Unit 1614

U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA	2003/0073703	04/17/03	Coghlan et al.	514	257	07/23/02
	AB	Re 28,819	05/18/76	Thompson	514	174	04/16/75
	AC	3,710,795	01/16/73	Higuchi et al.	424	424	09/29/70
	AD	4,044,126	08/23/77	Cook et al.	514	180	07/09/76
	AE	4,328,245	05/04/82	Yu et al.	514	530	02/13/81
	AF	4,358,603	11/09/82	Yu	560	2	04/16/81
	AG	4,364,923	12/21/82	Cook et al.	424	46	04/30/81
	AH	4,409,239	10/11/83	Yu	514	530	01/21/82
	AI	4,410,545	10/18/83	Yu et al.	514	530	05/10/82
	AJ	4,414,209	11/08/83	Cook et al.	514	180	06/13/77
	AK	4,522,811	06/11/85	Eppstein et al.	514	2	07/08/82
	AL	4,981,784	01/01/91	Evans et al.	435	6	11/30/88
	AM	5,033,252	07/23/91	Carter	53	425	07/30/90
	AN	5,052,558	10/01/91	Carter	206	439	07/27/90
	AO	5,071,773	12/10/91	Evans et al.	436	501	10/20/87
	AP	5,323,907	06/28/94	Kalvelage	206	531	03/15/93
	AQ	5,506,102	04/09/96	McDonnell	435	6	10/28/93
	AR	5,688,810	11/18/97	Jones et al.	514	311	06/05/95
	AS	5,693,646	12/02/97	Jones et al.	514	285	06/05/95
	AT	5,696,127	12/09/97	Jones et al.	514	285	06/05/95
	AU	5,696,133	12/09/97	Jones et al.	514	314	06/05/95
	AV	6,068,976	05/30/00	Briggs et al.	435	6	03/19/96
	AW	6,380,207	04/30/02	Coghlan et al.	514	285	02/13/98
	AX	6,506,766	01/14/03	Coghlan et al.	514	285	07/05/02
	AY	6,696,459	02/24/04	Jones et al.	514	285	10/14/97

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/

Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 18202-027US1/1110US	Application No. 10/589,920
Information Disclosure Statement by Applicant (Use several sheets if necessary)	Applicant ZHI et al.	
(37 CFR §1.98(b))	Filing Date August 17, 2006	Group Art Unit 1614

Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation Yes	Translation No
	AZ	03/037905	05/08/03	PCT				
	BA	02/02565	01/10/02	PCT				
	BB	99/041257	08/19/99	PCT				
	BC	99/041256	08/19/99	PCT				
	BD	95/031722	11/23/95	PCT				
	BE	96/029405	09/26/96	PCT				
	BF	96/019458	06/27/96	PCT				
	BG	1053239	01/08/03	EP				
	BH	1053240	04/16/03	EP				
	BI	1382597	01/21/04	EP				

Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	BJ	Allegretto et al., "Transactivation properties of retinoic acid and retinoid X receptors in mammalian cells and yeast. Correlation with hormone binding and effects of metabolism," Journal of Biological Chemistry, 268(35):26625-26633, (1993). Erratum in: Journal of Biological Chemistry, 269(10):7834, (1994).
	BK	Ansel, H.C., *Introduction to Pharmaceutical Dosage Forms*, Fourth Edition, Lea and Febiger, Philadelphia, P.A., p. 126, (1985).
	BL	Bains and Tacke, "Silicon chemistry as a novel source of chemical diversity in drug design," Current Opinion in Drug Discovery and Development, 6(4):526-543, (2003).
	BM	Berger et al., "Interaction of glucocorticoid analogues with the human glucocorticoid receptor," Journal of Steroid Biochemistry and Molecular Biology, 41:733-748, (1992).
	BN	Cheng and Prusoff, "Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction," Biochemical Pharmacology, 22:3099-3108, (1973).
	BO	Edwards et al., "Preparation, resolution, and biological evaluation of 5-aryl-1,2-dihydro-5H-chromeno[3,4-f]quinolines potent, orally active, nonsteroidal progesterone receptor agonists," Journal of Medicinal Chemistry, 41(15):2779-2785, (1998).
	BP	Evans et al., "The steroid and thyroid hormone receptor superfamily," Science, 240:889-895, (1988).
	BQ	Fingl et al., *The Pharmacological Basis of Therapeutics*, Ch. 1, Eds. Goodman and Gilman, Macmillan Publishing Co., New York, N.Y., pp. 1-46, (1975).
	BR	Nogrady, T., *Medicinal Chemistry A Biochemical Approach*, Oxford University Press, New York, N.Y., pp. 388-392, (1985).

Examiner Signature	Date Considered

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No.	Application No.
Information Disclosure Statement by Applicant (Use several sheets if necessary)		18202-027US1/1110US	10/589,920
		Applicant ZHI et al.	
(37 CFR §1.98(b))		Filing Date August 17, 2006	Group Art Unit 1614

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
	BS	O'Reilly et al., "Cotransfection and recombinant virus identification" in *Baculovirus Expression Vectors*, Ch. 13, O'Reilly et al., Eds., W. H. Freeman, New York, N.Y., pp. 139-179, (1992).
	BT	Pathirana et al., "Nonsteroidal human progesterone receptor modulators from the marine alga Cymopolia barbatam," Molecular Pharmacology, 47:630-635, (1995).
	BU	Pooley et al., "Discovery and preliminary SAR studies of a novel, nonsteroidal progesterone receptor antagonist pharmacophore," Journal of Medicinal Chemistry, 41:3461-3466, (1998).
	BV	Srinivasan and Thompson, "Overexpression of full-length human glucocorticoid receptor in Spodoptera frugiperda cells using the baculovirus expression vector system," Molecular Endocrinology, 4(2):209-216, (1990).
	BW	Tacke and Zilch, "Sila-substitution--a useful strategy for drug design?" Endeavour, 10:191-197, (1986).
	BX	Tegley et al., "5-Benzylidene 1,2-dihydrochromeno[3,4-f]quinolines, a novel class of nonsteroidal human progesterone receptor agonists," Journal of Medicinal Chemistry, 41(22):4354-4359, (1998).
	BY	Zhi et al., "5-Alkyl 1,2-dihydrochromeno[3,4-f]quinolines a novel class of nonsteroidal progesterone receptor modulators," Bioorganic and Medicinal Chemistry Letters, 8(23):3365-3370, (1998).
	BZ	Zhi et al., "5-Aryl-1,2,3,4-tetrahydrochromeno[3,4-f]quinolin-3-ones as a novel class of nonsteroidal progesterone receptor agonists effect of A-ring modification," Journal of Medicinal Chemistry, 42(8):1466-1472, (1999).
	CA	Zhi et al., "5-Aryl-1,2-dihydrochromeno[3,4-f]quinolines a novel class of nonsteroidal human progesterone receptor agonists," Journal of Medicinal Chemistry, 41(3):291-302, (1998).
	CB	Zhi et al., "5-benzylidene-1,2-dihydrochromeno[3,4-f]quinolines as selective progesterone receptor modulators," Journal of Medicinal Chemistry, 46(19):4104-4112, (2003).
	CC	Zhi et al., "Development of progesterone receptor antagonists from 1,2-dihydrochromeno[3,4-f]quinoline agonist pharmacophore," Bioorganic and Medicinal Chemistry Letters, 13(12):2075-2078, (2003).
	CD	Zhi et al., "Synthesis and biological activity of 5-methylidene1,2-dihydrochromeno[3,4-f]quinoline derivatives as progesterone receptor modulators," Bioorganic and Medicinal Chemistry Letters, 13(12):2071-2074, (2003).
	CE	Zhi et al., "Nonsteroidal progesterone receptor antagonists based on 6-thiophenehydroquinolines," Bioorganic and Medicinal Chemistry Letters, 10:415-418, (2000).

Examiner Signature	/Timothy Thomas/	Date Considered	08/19/2008

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Disclosure Form (PTO-1449)

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /TPT/